Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Equivocal HbA1c Test Results Increases Risk of Neonatal Hypoglycemia

By LabMedica International staff writers
Posted on 10 Sep 2020
Maternal diabetes, including gestational diabetes, typically diagnosed by an oral glucose tolerance test in the second trimester, is a known risk factor for neonatal hypoglycemia and infants born large for gestational age.

Clinicians have suspected that some infants born to mothers without overt diabetes or gestational diabetes may still have an increased risk for hypoglycemia and tend to be larger at birth. More...
However, this has not been systematically evaluated during pregnancy, especially in the context of long-term glucose control in pregnant women.

Pediatricians at the Hurley Children’s Hospital (Flint, MI, USA) and their colleagues analyzed data from 4,769 infants born at 34 weeks’ gestation or later at Hurley Medical Center from 2015 to April 2018, including 21,482 blood glucose measurements. The mean gestational age at delivery, 37.3 weeks; 63% were delivered vaginally; 54% were white; 50% male neonates). Glycated hemoglobin (HbA1c) values were available for 4,391 mothers with 6,312 measurements during pregnancy. Mothers and infants were stratified into four groups: mothers without documented pregnancy conditions; prenatal exposure to beta-blockers; prenatal exposure to diabetes; or prenatal exposure to beta-blockers and diabetes.

The team noted that within the cohort, 4.9% of infants were born large for gestational age. Among infants born to mothers with no documented pregnancy conditions, they observed a statistically significant relationship between pregnancy HbA1c level and birth weight for white and black infants. They found that, overall, third trimester HbA1c was higher among mothers whose infants had hypoglycemia versus. mothers whose infants did not have hypoglycemia (mean, 5.3% versus 5.1%); with the trend manifesting at a lower HbA1c level for infants born to white mothers (mean HbA1c, 5.2%) versus black mothers (mean HbA1c, 5.4%).

Among infants born to white mothers, increases in HbA1c levels from 4.8% to 6% increased the risk for hypoglycemia from 25% to 48% in late preterm, and from 12% to 22% in term deliveries. Among infants born to black mothers, the same maternal HbA1c range increased hypoglycemia risk from 15% to 26% in late preterm and from 5% to 10% in deliveries. Additionally, each 0.1% increase in HbA1c levels between 4.8% and 6% increased the odds of neonatal hypoglycemia by 6.4% among blank infants and by 12% among white infants.

Venkatesh Sampath, MD, MRCPCh, a Professor of Pediatrics and the senior author of the study, said, “For clinicians, these findings, if confirmed in prospective study, can help identify at-risk infant populations who would need closer monitoring to prevent early neonatal hypoglycemia. Clinicians may consider routine screening of HbA1c of mothers and incorporate such testing into clinical practice. Such measure may decrease the incidence of hypoglycemia potentially, a common clinical problem in the neonate.”

The authors concluded that Pregnancy HbA1c levels between 4.8%-6.0% considered acceptable during pregnancy impacts neonatal hypoglycemia and birth weight especially in Caucasian race. A third trimester HbA1c greater than 5.2% is a potential risk factor for neonatal hypoglycemia, especially in preterm infants. The study was published on August 12, 2020 in The Journal of Pediatrics.

Related Links:
Hurley Children’s Hospital


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.